Table 1 Patient characteristics at diagnosis.
All patients (N = 113) | |
|---|---|
Age, years—median, range | 67 (16–88) |
Age > 60 years—n (%) | 75 (66.4) |
Male—n (%) | 75 (66.4) |
Diagnosis—n (%) | |
PTCL-NOS | 78 (69.0) |
ALK-positive ALCL | 9 (8.0) |
ALK-negative ALCL | 5 (4.4) |
AITL | 15 (13.3) |
EATL | 5 (4.4) |
HSTL | 1 (0.9) |
ECOG PS ≥ 2—n (%) | 33 (29.2) |
B symptoms—n (%) | 52 (46.0) |
Elevated LDH (> ULN)—n (%) | 71 (62.8) |
Ann Arbor Stage III/IV—n (%) | 90 (79.6) |
Extranodal sites ≥ 2—n (%) | 29 (25.7) |
BM involvement—n (%) | 27 (23.9) |
IPI—n (%) | |
Low (0, 1) | 23 (20.4) |
Low-intermediate (2) | 22 (19.5) |
High-intermediate (3) | 42 (37.2) |
High (4, 5) | 26 (23.0) |
PIT—n (%) | |
Group 1 (0) | 12 (10.6) |
Group 2 (1) | 32 (28.3) |
Group 3 (2) | 41 (36.3) |
Group 4 (3, 4) | 28 (24.8) |
First treatment | |
CHOP | 59 (52.2) |
THP-COP | 49 (43.4) |
Other | 5 (4.4) |
Upfront auto-SCT | 12 (10.6) |
